TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10386195

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400‐800 mg/d p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8926223

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (differential reinforcement of appropriate behavior and guided compliance)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combined effects of behavioral intervention and methylphenidate
Number of subjects: 3
Study: 1520082

Group type: EXPERIMENTAL
Intervention: Threonine at a total daily dose of 7.5 g
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Threonine
Number of subjects: 26
Study: 6873148

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg at 20 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin 75 mg at 8 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin 75 mg at 12 h
Number of subjects: 0
Study: 29756695

Group type: EXPERIMENTAL
Intervention: Stimulating catheter (Stim group, N=36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nonstimulating catheter (Nonstim group, N=36)
Number of subjects: 72
Study: 27806013

Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 86
Study: 25833885

Group type: EXPERIMENTAL
Intervention: Modeling group (n = 160)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Validation group (n = 247)
Number of subjects: 407
Study: 23093133

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20868641

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Second-generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Perphenazine (first-generation antipsychotic)
Number of subjects: 1460
Study: 17940309

Group type: EXPERIMENTAL
Intervention: Preganglionic TFESI (at the supraadjacent intervertebral disk level)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Ganglionic TFESI (at the location of the exiting nerve root)
Number of subjects: 239
Study: 15531056

Group type: EXPERIMENTAL
Intervention: Class 1 obese subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Body mass index correlation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dynamic pedobarographic parameters
Number of subjects: 50
Study: 12351450

Group type: EXPERIMENTAL
Intervention: C-peptide (6 pmol x kg(‐1) x min(‐1)) during 60 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline during 60 min
Number of subjects: 8
Study: 10543928

Group type: EXPERIMENTAL
Intervention: ramipril 5 mg/day
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: ramipril 1.25 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study: 7558732

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Iopamidol and Ioxaglate
Number of subjects: 142
Study: 2207219

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (CMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6447269

Group type: EXPERIMENTAL
Intervention: SCH 1000 (40 microgram ipratropium bromide)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 microgram)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6392223

Group type: EXPERIMENTAL
Intervention: AT1727 as a radiosensitizer
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: AT1727 in soft tissue sarcomas
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: AT1727 in lung cancer
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: AT1727 in esophageal cancer
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: AT1727 in nasopharyngeal cancer
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: AT1727 treatment side effects
Number of subjects: 89

Group type: COMPARATOR
Intervention: Comparison of lung fibrosis rate
Number of subjects: 89
Study: 29975672

Group type: EXPERIMENTAL
Intervention: Conflict resolution training session (3 hours)
Number of subjects: 60
Study: 26724833

Group type: EXPERIMENTAL
Intervention: Two 20-min bouts of moderate-intensity physical activity
Number of subjects: 56

Group type: COMPARATOR
Intervention: One 20-min bout of moderate-intensity physical activity
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (sitting all morning)
Number of subjects: 56
Study: 24927259

Group type: EXPERIMENTAL
Intervention: Bilirubin/albumin (B/A) ratio and total serum bilirubin (TSB) thresholds
Number of subjects: 615

Group type: COMPARATOR
Intervention: Total serum bilirubin (TSB) thresholds only
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: B/A ratio
Number of subjects: 615

Group type: COMPARATOR
Intervention: TSB
Number of subjects: 615
Study: 23113947

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate granules (60/20 mg) once daily for three days
Number of subjects: 535

Group type: COMPARATOR
Intervention: Artemether-lumefantrine crushed tablets (20/120 mg) twice daily for three days
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 535

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 535
Study: 19648772

Group type: EXPERIMENTAL
Intervention: Domperidone (0.3 mg/kg/8 h p.o. for at least 2 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 22
Study: 18348296

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy after primary surgery
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Older age (>/=60 years)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Stage II cancer
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Grade 2 cancer
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Grade 3 cancer
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Positive cytology
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Prognostic index based on risk factors
Number of subjects: 506
Study: 15785069

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0
Study: 12509376

Group type: EXPERIMENTAL
Intervention: Pharmacists consulting to family physicians for medication optimization
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (no pharmacist consultation)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Mean systolic blood pressure
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Medication use, health care utilization, and general health
Number of subjects: 720
Study: 10594068

Group type: EXPERIMENTAL
Intervention: Conditioned Stimuli (CS+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonconditioned Stimuli (CS-)
Number of subjects: 0
Study: 7532157

Group type: EXPERIMENTAL
Intervention: Intra-arterial hepatic route (i.a.h.) administration of Cisplatin (CDDP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intravenous (i.v.) administration of Cisplatin (CDDP)
Number of subjects: 22
Study: 1821700

Group type: EXPERIMENTAL
Intervention: Loading dose of milnacipran (300 mg daily for 2 weeks, then 150 mg daily for 2 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard regimen of milnacipran (200 mg daily for 4 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluvoxamine (200 mg daily for 4 weeks)
Number of subjects: 120
Study: 6896140

Group type: EXPERIMENTAL
Intervention: Massaging the nasolacrimal sac to increase hydrostatic pressure and rupture the membranous obstruction
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Simple obstructions in the nasolacrimal duct
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Silicone intubation of the nasolacrimal system
Number of subjects: 132

Group type: COMPARATOR
Intervention: Simple massage
Number of subjects: 132

Group type: COMPARATOR
Intervention: No massage
Number of subjects: 132
Study: 31871108

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000 IU/day)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 31088405

Group type: EXPERIMENTAL
Intervention: MATESmobile + face-to-face training
Number of subjects: 590

Group type: COMPARATOR
Intervention: Face-to-face training
Number of subjects: 590
Study: 29017527

Group type: EXPERIMENTAL
Intervention: ParentCorps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pre-kindergarten programming
Number of subjects: 0
Study: 27140216

Group type: EXPERIMENTAL
Intervention: Midazolam sequential with dexmedetomidine (loading dose of midazolam at 0.3-3 mg/kg·h for 24 h before extubation, followed by dexmedetomidine infusion at 0.2-1 μg/kg·h until extubation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam (0.3-3 mg/kg·h until extubation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam sequential with dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 80
Study: 24815795

Group type: EXPERIMENTAL
Intervention: Sildenafil (titrated to 80 mg, three times daily, as tolerated)
Number of subjects: 0
Study: 22348451

Group type: EXPERIMENTAL
Intervention: Low-dose melatonin (0.4mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-dose melatonin (4.0mg)
Number of subjects: 27
Study: 18822087

Group type: EXPERIMENTAL
Intervention: Apomorphine infusion
Number of subjects: 4

Group type: COMPARATOR
Intervention: Levodopa infusion
Number of subjects: 4
Study: 17473042

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FL Bond
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 60
Study: 15190731

Group type: EXPERIMENTAL
Intervention: Prenatal hypnosis
Number of subjects: 520

Group type: COMPARATOR
Intervention: Attention-only group
Number of subjects: 520
Study: 11357167

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) 150 mg/d
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: IL-1ra (various dosages)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: IL-1ra 1.0 mg/kg/d
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: IL-1ra 2.0 mg/kg/d
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 9580575

Group type: EXPERIMENTAL
Intervention: 25 mg LAAM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75 mg LAAM
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8111576

Group type: EXPERIMENTAL
Intervention: 0.1 N HCl
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HCl infusion (patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 4% lignocaine
Number of subjects: 22
Study: 3168576

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31160807

Group type: EXPERIMENTAL
Intervention: Second allogeneic hematopoietic cell transplant (allo‐HCT)
Number of subjects: 0
Study: 31023084

Group type: EXPERIMENTAL
Intervention: Exercise training (150 min per week)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Albuminuria patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 75
Study: 28089672

Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Number of subjects: 1102

Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol
Number of subjects: 1102
Study: 25594912

Group type: EXPERIMENTAL
Intervention: Strength training using exercises at the same intensity
Number of subjects: 90

Group type: COMPARATOR
Intervention: Strength training using exercises of varying intensity
Number of subjects: 90
Study: 23686001

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) associated with intravitreal bevacizumab (IVB) injections
Number of subjects: 42

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) alone
Number of subjects: 42
Study: 20946162

Group type: EXPERIMENTAL
Intervention: Early rehabilitation (sildenafil citrate twice weekly starting at 2 months postoperatively)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Late rehabilitation (sildenafil citrate twice weekly starting at 6 months postoperatively)
Number of subjects: 18
Study: 19941182

Group type: EXPERIMENTAL
Intervention: Perceived deviations during simple machine work
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Perceived deviations during complex machine work
Number of subjects: 12
Study: 16381002

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: High HIF‐1α expression in lymph node-positive patients and NHG 1/2 tumours
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: High HIF‐1α expression in NHG 1/2 tumours
Number of subjects: 377

Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 377
Study: 15263787

Group type: EXPERIMENTAL
Intervention: Hydrophilic catheter (group B, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard catheter (group A, n = 50)
Number of subjects: 100
Study: 11419823

Group type: EXPERIMENTAL
Intervention: Standard U.S. 13C‐urea breath test (125 mg of 13C‐urea, pudding test meal, breath sample taken 30 min after ingestion)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Simplified UBT‐Lite (75 mg of 13C‐urea, 2.5-g citric acid test meal, breath sample taken 15 min after ingestion)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Prior meals versus fasting with UBT‐Lite
Number of subjects: 259
Study: 9060555

Group type: EXPERIMENTAL
Intervention: Autotransplant (CBV regimen: cyclophosphamide, carmustine, and etoposide)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Autotransplant (CBV regimen)
Number of subjects: 541
Study: 8376441

Group type: EXPERIMENTAL
Intervention: Gamma locking nail
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dynamic Hip Screw
Number of subjects: 200
Study: 3545173

Group type: EXPERIMENTAL
Intervention: Dalkon Shield
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: 7Cu200
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Latex Leaf
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: ML Cu250
Number of subjects: 843
Study: 31553254

Group type: EXPERIMENTAL
Intervention: Low-dose EGF
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High-dose EGF
Number of subjects: 3

Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low-dose EGF vs High-dose EGF
Number of subjects: 3
Study: 28059565

Group type: EXPERIMENTAL
Intervention: message reception and expression (treatment group)
Number of subjects: 201

Group type: COMPARATOR
Intervention: campaign message reception only (control group)
Number of subjects: 201
Study: 25794236

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoenergetic placebo (PLA)
Number of subjects: 16
Study: 25116984

Group type: EXPERIMENTAL
Intervention: Tai chi training
Number of subjects: 66

Group type: COMPARATOR
Intervention: Educational control intervention
Number of subjects: 66
Study: 22434756

Group type: EXPERIMENTAL
Intervention: HFF > 5% (n = 16)
Number of subjects: 41

Group type: COMPARATOR
Intervention: HFF ≤ 5% (n = 25)
Number of subjects: 41
Study: 19075089

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study: 17690485

Group type: EXPERIMENTAL
Intervention: 100 mg of hop water extract (HWE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15694055

Group type: EXPERIMENTAL
Intervention: Intramuscular etofenamate (1 g/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intramuscular diclofenac (75 mg/day)
Number of subjects: 110
Study: 11340108

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Non-night blind women (all supplementation groups combined)
Number of subjects: 10000
Study: 7980884

Group type: EXPERIMENTAL
Intervention: Home detoxification
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inpatient detoxification
Number of subjects: 20
Study: 2923424

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of morphine sulphate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of ketamine hydrochloride
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined continuous subcutaneous infusion of morphine sulphate and ketamine hydrochloride
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate
Number of subjects: 32
Study: 31494365

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 1.0 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam (control)
Number of subjects: 60
Study: 31073521

Group type: EXPERIMENTAL
Intervention: Amnion group
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PDLLA group
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 28116886

Group type: EXPERIMENTAL
Intervention: Pycnogenol® 100mg/day for 8 weeks
Number of subjects: 35
Study: 22967997

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 228

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CBDCA/PTX)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Platinum throughout treatment
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Gefitinib, platinum, and pemetrexed (PEM) or docetaxel (DOC)
Number of subjects: 228
Study: 21485669

Group type: EXPERIMENTAL
Intervention: NPPV (Non-invasive positive pressure ventilation)
Number of subjects: 40
Study: 19272441

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Stress condition (mental tasks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rest condition
Number of subjects: 59
Study: 16484565

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 12627259

Group type: EXPERIMENTAL
Intervention: Amifostine (group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 36
Study: 10705078

Group type: EXPERIMENTAL
Intervention: Insulin (euglycemic hyperinsulinemic clamping)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin (stopped after clamping)
Number of subjects: 5
Study: 9159690

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose (Hymecel)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1.4% sodium hyaluronate (Healon GV)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 4% sodium chondroitin sulfate‐3% sodium hyaluronate (Viscoat)
Number of subjects: 66
Study: 7910888

Group type: EXPERIMENTAL
Intervention: World Health Organization partograph with an agreed labour-management protocol
Number of subjects: 35484
Study: 2895663

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study: 29458931

Group type: EXPERIMENTAL
Intervention: Horticultural therapy program (10 sessions, once a week from April 2017 to June 2017)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 26660337

Group type: EXPERIMENTAL
Intervention: Low-intensity wheelchair training (30-40% heart rate reserve, twice a week, for 30 min per session)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 29
Study: 25592012

Group type: EXPERIMENTAL
Intervention: Folic acid 800 μg/d
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 23323790

Group type: EXPERIMENTAL
Intervention: SagaPro
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 21924547

Group type: EXPERIMENTAL
Intervention: Gemcitabine alone (GEM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gemcitabine plus oxaliplatin (GEMOX)
Number of subjects: 44
Study: 18438894

Group type: EXPERIMENTAL
Intervention: Graded activity intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 16575723

Group type: EXPERIMENTAL
Intervention: Gentamicin plus doxycycline (DG regimen)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Streptomycin plus doxycycline (DS regimen)
Number of subjects: 191
Study: 14974365

Group type: EXPERIMENTAL
Intervention: Reduced dose of CyA and daclizumab (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal dose of CyA without daclizumab (group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 11045301

Group type: EXPERIMENTAL
Intervention: Intraperitoneal urokinase (5000 IU intraluminally in the peritoneal catheter, left for 4 hours before next exchange)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no urokinase)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intraperitoneal urokinase
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 9363911

Group type: EXPERIMENTAL
Intervention: Azelastine (4 mg/day)
Number of subjects: 24